Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003752 · ClinicalTrials.gov registry record · Phase 2
Bexarotene in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00003752 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 180 participants.
The verdict
NCT00003752, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.
Interventions
- DRUG bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 1998-10 |
| Est. Completion | 2003-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003752
The ClinicalTrials.gov registry entry for NCT00003752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bexarotene is the first listed.
NCT00003752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003752 about?
NCT00003752 is a clinical study titled "Bexarotene in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.
What is the current status of trial NCT00003752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 1998-10. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00003752?
The interventions under investigation include: bexarotene (DRUG).
Who is sponsoring clinical trial NCT00003752?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.